Norman S. Miller

Dr. Norman S. Miller

Department of Psychiatry, Medical College of Georgia, Augusta University, GA 30912, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2000 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
Norman S. MillerNorman S. Miller
Norman S. Miller
JFJoseph A. Flaherty
Joseph A. Flaherty

1 January 2004 in American Journal of Therapeutics
Verified
Journal Article
Closed access
Norman S. MillerNorman S. Miller
Norman S. Miller
AGAndrea Greenfeld
Andrea Greenfeld
The purpose of the study was to document the substantial increase in problematic use of hydrocodone and oxycodone in an addiction treatment population. Our study consisted of a retrospective review of medical records from all patients admitted and discharged in 2000 from Sparrow/St. Lawrence Addiction Detoxification Unit (N = 534). A literature review was conducted in medical journals, governmental groups, and reports including Drug Abuse Warning Network, Pharmacy Times, and National Household Survey on Drug Abuse. More than 144 patients (27%) were dependent on prescription opiate medications. The most frequently mentioned medication was Vicodin (hydrocodone) (53% of the users) followed by OxyContin (oxycodone) (19%). Physicians commonly prescribed these medications (75% of the cases). Predictors of dependence on opiate medications included substance-related diagnoses, positive toxicology for opiates, and other medical diagnoses. Patients under the care of physicians who have other drug dependence diagnoses and medical complaints appear at risk of developing dependence on prescription opiate medications. Proper evaluation and intervention can limit adverse consequences of prescription opiate medications.

Norman S. MillerNorman S. Miller
Norman S. Miller
RIRedon Ipeku
Redon Ipeku
TOThersilla Oberbarnscheidt
Thersilla Oberbarnscheidt
Marijuana is the most consumed illicit drug in the world, with over 192 million users. Due to the current legalization push of marijuana in the United States, there has been a lack of oversight regarding its public health policies, as marijuana advocates downplay the drug’s negative effects. This paper’s approach is from a public health perspective, focusing specifically on the cases of violence amongst some marijuana users. Here, we present 14 cases of violence with chronic marijuana users that highlight reoccurring consequences of: marijuana induced paranoia (exaggerated, unfounded distrust) and marijuana induced psychosis (radical personality change, loss of contact with reality). When individuals suffering from pre-existing medical conditions use marijuana in an attempt to alleviate their symptoms, ultimately this worsens their conditions over time. Although marijuana effects depend on the individual’s endocannabinoid receptors (which control behavioral functions, like aggression) and the potency level of tetrahydrocannabinol (THC) in the drug, scientifically documented links between certain marijuana users and violence do exist. Wider public awareness of the risks and side effects of marijuana, as well as a more prudent health policy, and government agency monitoring of the drug’s composition, creation, and distribution, are needed and recommended.

1 June 1999 in Psychiatric Clinics of North America
Verified
Journal Article
Closed access
Norman S. MillerNorman S. Miller
Norman S. Miller
LSLorinda M. Sheppard
Lorinda M. Sheppard

9 November 1994 in Alcoholism Treatment Quarterly
Verified
Journal Article
Closed access
Norman S. MillerNorman S. Miller
Norman S. Miller
NHNorman G. Hoffmann
Norman G. Hoffmann

1 July 1999 in The American Journal on Addictions
Verified
Journal Article
Closed access
PDF file
Norman S. MillerNorman S. Miller
Norman S. Miller
FNFred Ninonuevo
Fred Ninonuevo
NHNorman G. Hoffmann
Norman G. Hoffmann
BABoris M. Astrachan
Boris M. Astrachan
We sought to determine the impact of a lifetime diagnosis of major depression on addiction treatment outcome. Structured interviews were conducted upon admission, and consecutive structured interviews were conducted prospectively for treatment outcome at 6 and 12 month follow‐up periods. A multisite evaluation study of patients undergoing addiction treatment for alcohol and drug dependence was conducted in private outpatient facilities. Two thousand twenty‐nine subjects from 33 independent programs were enrolled in a national registry for addiction treatment outcomes. The patients received abstinence‐based addiction treatment with referral to a 12‐step recovery program, often Alcoholics Anonymous, and continuing care in the treatment programs. The outcome areas measured were treatment completion, posttreatment substance use, exposure to psychosocial relapse risk factors, involvement with continuing care (formal aftercare and peer support groups), and posttreatment vocational functioning, health care utilization, and legal involvement. The prevalence rate of depressive symptoms over at least a 2‐week period (major depression) in our sample was 28%. Multivariate analysis with stepwise multiple regression indicated that the most powerful predictors (relatively) of posttreatment alcohol/drug use were peer support group attendance and program continuing care involvement. Lifetime depression by itself and in interaction with each of these factors accounted for less than 2% of the variance in outcome. Logistic regression yielded similar results in the prediction of abstinence versus relapse. Posttreatment more than pretreatment factors appear to be more decisive in predicting risk for relapse.